Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial-Reference-Cited by-同舟云学术

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

Published:2013-12 Issue:4 Volume:1 Page:284-294
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Rigby Mark R,DiMeglio Linda A,Rendell Marc S,Felner Eric I,Dostou Jean M,Gitelman Stephen E,Patel Chetanbabu M,Griffin Kurt J,Tsalikian Eva,Gottlieb Peter A,Greenbaum Carla J,Sherry Nicole A,Moore Wayne V,Monzavi Roshanak,Willi Steven M,Raskin Philip,Moran Antoinette,Russell William E,Pinckney Ashley,Keyes-Elstein Lynette,Howell Michael,Aggarwal Sudeepta,Lim Noha,Phippard Deborah,Nepom Gerald T,McNamara James,Ehlers Mario R

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference28 articles.

1. Genetics, pathogenesis and clinical interventions in type 1 diabetes;Bluestone;Nature,2010

2. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial;Steffes;Diabetes Care,2003

3. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial;Feutren;Lancet,1986

4. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes;Cook;Diabetes,1989

5. Cyclosporine A for the treatment of new-onset insulin-dependent diabetes mellitus;Chase;Pediatrics,1990

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dépistage et prise en charge du diabète de type 1 préclinique, stade 1–2. Prise de position d’experts français;Médecine des Maladies Métaboliques;2024-09

2. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial;Nature Medicine;2024-07-30

3. Sequential immunotherapy: towards cures for autoimmunity;Nature Reviews Drug Discovery;2024-06-05

4. Immunotherapy options for type 1 diabetes in children and adolescents;Pediatrie pro praxi;2024-04-08

5. Tipping the balance in autoimmunity: are regulatory t cells the cause, the cure, or both?;Molecular and Cellular Pediatrics;2024-03-20